Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Momelotinib - Sierra Oncology

Drug Profile

Momelotinib - Sierra Oncology

Alternative Names: CYT-387; GS-0387; Momelotinib dihydrochloride

Latest Information Update: 13 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytopia Research
  • Developer Gilead Sciences
  • Class Antineoplastics; Benzamides; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Pancreatic cancer; Polycythaemia vera
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 07 Dec 2019 Updated efficacy data from the phase III SIMPLY-1 trial in Myelofibrosis released by Sierra Oncology
  • 20 Nov 2019 Sierra Oncology initiates enrolment in the phase III MOMENTUM trial for Myelofibrosis (Treatment-experienced) in USA (PO) (NCT04173494)
  • 07 Nov 2019 Sierra Oncology and Gilead Sciences amend Asset Purchase Agreement for Momelotinib
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top